Switch theme
Sign up to access all valuation multiples
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
2005
44
LTM Revenue $6.0M
Last FY EBITDA -$68.4M
$532M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Arbutus Biopharma has a last 12-month revenue (LTM) of $6.0M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Arbutus Biopharma achieved revenue of $6.2M and an EBITDA of -$68.4M.
Arbutus Biopharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Arbutus Biopharma valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $6.0M | XXX | $6.2M | XXX | XXX | XXX |
| Gross Profit | $6.0M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$68.4M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -1108% | XXX | XXX | XXX |
| EBIT | -$65.0M | XXX | -$70.0M | XXX | XXX | XXX |
| EBIT Margin | -1078% | XXX | -1134% | XXX | XXX | XXX |
| Net Profit | -$60.7M | XXX | -$69.9M | XXX | XXX | XXX |
| Net Margin | -1006% | XXX | -1133% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Arbutus Biopharma's stock price is $3.
Arbutus Biopharma has current market cap of $644M, and EV of $532M.
See Arbutus Biopharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $532M | $644M | XXX | XXX | XXX | XXX | $-0.33 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Arbutus Biopharma has market cap of $644M and EV of $532M.
Arbutus Biopharma's trades at 86.2x EV/Revenue multiple, and -7.8x EV/EBITDA.
Equity research analysts estimate Arbutus Biopharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Arbutus Biopharma has a P/E ratio of -10.6x.
See valuation multiples for Arbutus Biopharma and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $644M | XXX | $644M | XXX | XXX | XXX |
| EV (current) | $532M | XXX | $532M | XXX | XXX | XXX |
| EV/Revenue | 88.2x | XXX | 86.2x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -7.8x | XXX | XXX | XXX |
| EV/EBIT | -8.2x | XXX | -7.6x | XXX | XXX | XXX |
| EV/Gross Profit | 88.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | -10.6x | XXX | -9.2x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -8.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialArbutus Biopharma's last 12 month revenue growth is -7%
Arbutus Biopharma's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $1.7M for the same period.
Arbutus Biopharma's rule of 40 is -398% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Arbutus Biopharma's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Arbutus Biopharma and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -7% | XXX | -7% | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -1108% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -398% | XXX | -1115% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.7M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 876% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 1234% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Arbutus Biopharma acquired XXX companies to date.
Last acquisition by Arbutus Biopharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Arbutus Biopharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Arbutus Biopharma founded? | Arbutus Biopharma was founded in 2005. |
| Where is Arbutus Biopharma headquartered? | Arbutus Biopharma is headquartered in United States of America. |
| How many employees does Arbutus Biopharma have? | As of today, Arbutus Biopharma has 44 employees. |
| Who is the CEO of Arbutus Biopharma? | Arbutus Biopharma's CEO is Ms. Lindsay Androski, C.F.A.,J.D.,M.B.A.. |
| Is Arbutus Biopharma publicy listed? | Yes, Arbutus Biopharma is a public company listed on NAS. |
| What is the stock symbol of Arbutus Biopharma? | Arbutus Biopharma trades under ABUS ticker. |
| When did Arbutus Biopharma go public? | Arbutus Biopharma went public in 2007. |
| Who are competitors of Arbutus Biopharma? | Similar companies to Arbutus Biopharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Arbutus Biopharma? | Arbutus Biopharma's current market cap is $644M |
| What is the current revenue of Arbutus Biopharma? | Arbutus Biopharma's last 12 months revenue is $6.0M. |
| What is the current revenue growth of Arbutus Biopharma? | Arbutus Biopharma revenue growth (NTM/LTM) is -7%. |
| What is the current EV/Revenue multiple of Arbutus Biopharma? | Current revenue multiple of Arbutus Biopharma is 88.2x. |
| Is Arbutus Biopharma profitable? | Yes, Arbutus Biopharma is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
